Well here you go Tim,hot off the press!!!
Procyon BioPharma Announces Formation Of Its Scientific Advisory Board
LONDON, ON, March 16 /CNW/ - Procyon BioPharma Inc. (ASE: PBP) is pleased
to announce the formation of its Scientific Advisory Board (SAB). The SAB
includes scientists who are renowned experts in areas of specialty critical to
Procyon. Under the chairmanship of Dr. Arthur Porter, Chairman, Department of
Radiation Oncology at Wayne State University School of Medicine, the members
of the SAB are Dr. Iain Cleator, Professor of Surgery, University of British
Columbia, Dr. Zeev Estrov, Director of Hematopoiesis Research, M.D. Anderson
Cancer Center, Dr. Stuart Maddin, Clinical Professor Emeritus, Division of
Dermatology at the Faculty of Medicine, University of British Columbia and Dr.
Kenneth Pienta, Professor of Internal Medicine, Division of
Hematology/Oncology at the University of Michigan Medical School.
''Our Scientific Advisory Board brings together a distinguished panel of
medical professionals, all of whom are leaders in their respective fields,''
said Dr. Chandra Panchal, President and Chief Executive Officer of Procyon.
''Their extensive clinical experience as well as outstanding research
capabilities will be of tremendous value to Procyon BioPharma as we evaluate
the therapeutic and diagnostic opportunities available to us from the
development of our anti-cancer platform technologies. In addition, their
counsel will serve us well as we evaluate the opportunities presented by our
late stage products, FIBROSTAT(TM) and COLOPATH(TM).''
''Procyon BioPharma has an exciting portfolio of technologies and late
stage products,'' said Dr. Porter. ''I am confident that our guidance and
advice will add significant value to the Company. Our knowledge across all
areas of the Company's science, together with our understanding of clinical
trials and patient needs, will be helpful to Procyon in making progress toward
its short and long term objectives.''
Dr. Arthur Porter, MD, is Chairman, Department of Radiation Oncology at
Wayne State University School of Medicine, Detroit, Michigan. In addition, Dr.
Porter holds several other Faculty and Hospital appointments and is Executive
Vice-President and Chief Operating Officer at Detroit Medical Centre. He is
the President of the American Cancer Society Great Lakes Division and holds
various Society and Board positions. Dr. Porter's work has been published
extensively in medical publications, articles and books. His areas of special
interest include Genitourinary Oncology, Brachytherapy and Clinical Research.
Dr. Iain Cleator MB, CHB, is Professor of Surgery, University of British
Columbia, Vancouver, British Columbia. Dr. Cleator is active in many
professional associations and currently serves on the Board of Directors of
the British Columbia Medical Association and is a member of the British
Columbia Cancer Control Agency Colorectal Cancer Screening Committee. Dr.
Cleator is Head of the Gastrointestinal Clinic at St. Paul's Hospital in
Vancouver. Dr. Cleator is widely published and a recognized authority in the
area of colorectal cancer screening and has collaborated in the development of
screening tests with the pharmaceutical industry.
Dr. Zeev Estrov MD is Associate Professor of Medicine and Associate
Internist, Director of Hematopoiesis Research, Department of Bioimmunotherapy,
Division of Medicine at the University of Texas, M.D. Anderson Cancer Center.
Dr. Estrov is a very active researcher and his work has been published
extensively. He is an authority on hematologic malignancies, with much of his
research and publications in the area of leukemia.
Dr. Stuart Maddin, MD is Clinical Professor Emeritus, Division of
Dermatology at the Faculty of Medicine, University of British Columbia. A
former President of the Canadian Dermatology Association, he has also served
as a Director of the American Academy of Dermatology as well as
Secretary-General of the International Committee of Dermatology (I.L.D.S.). He
also held appointments as advisor to a number of regulatory agencies in Canada
and the U.S.A. Dr. Maddin is the editor of Skin Therapy Letter as well as the
author or co-author of several dermatological publications. Dr. Maddin has
consulted to a number of multi-national pharmaceutical companies and
organizations.
Dr. Kenneth Pienta MD is a Professor of Internal Medicine, Division of
Hematology/Oncology and Professor of Surgery, Division of Urology at the
University of Michigan Medical School, Ann Arbor, Michigan. Dr. Pienta is
recognized as an authority in the field of prostate cancer biology and
metastasis and has developed many of the treatments for hormone refractory
prostate cancer. He has an active clinical practice and has been recognized as
one of the ''Best Doctors in America'' by his peers. Dr. Pienta has over 200
publications in the area of prostate cancer and has received many awards and
recognition for his work. He is a six-time recipient of the Research Award by
the Association for the Cure of Cancer of the Prostate.
Procyon BioPharma is a biopharmaceutical company engaged in the discovery
and development of innovative products for the treatment and diagnosis of
cancer. Procyon BioPharma is advancing a broad pipeline of products based on
its proprietary Antinuclear Autoantibody (ANA) and Prostate Secretory Protein
(PSP(94)) technologies. The Company has two products in late-stage
development, COLOPATH(TM), a screening test for colorectal cancer, and
FIBROSTAT(TM), a topical therapeutic cream designed for the management of
excessive scars following surgery or serious burns. Procyon BioPharma is
headquartered in London, Ontario with research facilities in London, Ontario
and Boston, Massachusetts.
''The Alberta Stock Exchange has neither approved or disapproved the
information contained herein.''
|
